Today, Moderna have published in a press release their top-line findings looking at neutralising antibody responses from their Omicron-containing bivalent COVID-19 vaccine against the omicron subvariants BA.4 and BA.5.
Dr Paul Burton, Moderna’s Chief Medical Officer, was available on this call to answer journalists’ questions.
Please note that was early top-line data with no paper or preprint. The data is being submitted to regulators and for peer review publication.
Dr Paul Burton, Chief Medical Officer, Moderna